Immunic, Inc. Gears Up for Key Investor Conferences
Immunic, Inc. (Nasdaq: IMUX), a dynamic biotechnology firm known for its innovative development of orally administered therapies for chronic inflammatory and autoimmune diseases, has announced a strategic push to participate in prominent industry conferences this November. These events are pivotal for sharing insights about their current research and for engaging with potential investors, collaborators, and industry experts.
Highlights of Upcoming Conferences
BIO-Europe Conference
The BIO-Europe conference is scheduled from November 4 to 6. Members of Immunic's management, business development, and investor relations teams will be actively engaging in partnership discussions at this event. This conference is known for being a cornerstone for biotechnology companies and offers extensive networking opportunities. Immunic encourages those interested in scheduling meetings to utilize the BIO-Europe partnering portal.
Symposium on Immuno-Mediated Diseases
Following BIO-Europe, on November 8-9, Immunic will participate in the Symposium 238 dedicated to Immuno-Mediated Diseases of the GI Tract. Dr. Sara Elhag, an Associate Manager in Translational Pharmacology at Immunic, will present data from an ongoing phase 1b clinical trial of IMU-856, an innovative small molecule modulator targeting SIRT6 for the treatment of celiac disease. This presentation is an excellent opportunity to highlight Immunic’s progress in this crucial area of research.
One-on-One Meetings at Jefferies London Healthcare Conference
From November 19 to 21, Immunic's management and investor relations teams are set to host one-on-one meetings in connection with the Jefferies London Healthcare Conference. This event allows for deeper discussions about Immunic’s vision and the strategic direction of their clinical pipeline. Interested parties should reach out to the Immunic team to arrange meetings and discussions.
Virtual Investor Summit
On November 21, Daniel Vitt, the CEO of Immunic, will present a company overview during the Virtual Investor Summit. This presentation is essential for investors seeking an update on the company’s endeavors and progress in its clinical trials. Those interested can register for the conference and access the presentation through Immunic's “Events and Presentations” section on their website.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is at the forefront of advancing its clinical pipeline, focusing on therapies that target chronic inflammatory and autoimmune diseases. The lead development candidate, vidofludimus calcium (IMU-838), is undergoing phase 3 and phase 2 clinical trials for relapsing and progressive multiple sclerosis. This candidate highlights Immunic's dedication to improving the lives of patients suffering from various challenging conditions by leveraging first-in-class mechanisms of action and anti-inflammatory strategies.
Moreover, IMU-856 is positioned to address gastrointestinal ailments by focusing on restoring intestinal barrier function, thus potentially benefiting a wide range of gastrointestinal disorders, including celiac disease.
As Immunic continues to enhance its clinical pipeline and seeks new opportunities for partnership and investment, it invites stakeholders to learn more about its vision and progress through various engagement opportunities.
Frequently Asked Questions
What conferences is Immunic, Inc. participating in this November?
Immunic, Inc. will participate in BIO-Europe, Symposium 238, the Jefferies London Healthcare Conference, and the Virtual Investor Summit.
Who will represent Immunic at these conferences?
Members of Immunic's management, business development, and investor relations teams will represent the company and engage with industry professionals and investors.
What therapy is Dr. Sara Elhag presenting data on at the Symposium?
Dr. Sara Elhag will present data on IMU-856, a small molecule modulator intended for the treatment of celiac disease.
How can potential investors contact Immunic for meetings?
Potential investors can contact Immunic's Vice President of Investor Relations, Jessica Breu, to schedule one-on-one meetings, especially during the Jefferies London Healthcare Conference.
Where can I find more information on Immunic's clinical trials?
More information can be found on Immunic's official website, specifically under the “Events and Presentations” section, which provides updates on ongoing clinical trials and presentations.
